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Getting stuck or choosing to stay? 
Neutrophil transit times in the lung in 
acute inflammation and COPD
Elizabeth Sapey,   1 Robert A Stockley2
The neutrophil is generally recognised as a 
key cellular mediator in the pathophysi-
ology of chronic obstructive pulmonary 
disease (COPD). This is based on the 
propensity for the cell to release proin-
flammatory mediators including super-
oxide radicals and importantly serine 
proteinases. These products have been 
shown to replicate many of the patholog-
ical changes typical of COPD in cell-based 
and animal models1 and have significant 
potential for bystander tissue damage, 
especially when the neutrophil is primed 
or activated and degranulates more 
readily.2 Further, studies have consistently 
shown increased numbers of neutrophils, 
neutrophil-associated cytokines and 
neutrophil chemoattractants in COPD 
airway fluids (be they collected as sponta-
neous3 or induced sputum4 or as broncho-
alveolar lavage5) and the numbers of 
neutrophils and their products correlate 
with disease severity/activity, as deter-
mined by the degree of airway obstruc-
tion, decline in FEV1 (Forced Expiratory 
Volume in 1 Second) or severity of emphy-
sema present.6 Also, neutrophilia in COPD 
lung secretions is seen regardless of the 
clinical phenotype; although some pheno-
types are associated with a greater burden 
of neutrophilic inflammation or a reduced 
capacity for neutrophil proteinase inhibi-
tion, including those patients with chronic 
bronchitis, frequent exacerbators or those 
colonised with bacteria, as recently 
reviewed.7 However, this wealth of data 
supporting neutrophils in COPD patho-
genesis is tempered by two potentially 
conflicting observations. First, histological 
studies have not reported a neutrophilia 
within the airway wall in COPD8 and 
second, neutrophils are avid phagocytes 
but COPD patients are still commonly 
colonised with potentially pathogenic 
bacteria.9 This leads to several key ques-
tions. (1) Do neutrophils accumulate in 
the lungs in COPD? (2) If so, where? (3) 
Why are they there? (4) Can therapeutics 
modulate neutrophil accumulation to 
preserve host health?
The neutrophil is usually considered a 
transitory rather than tissue resident cell, 
migrating to areas of inflammation and 
infection on demand (although recent 
studies have identified a resident neutro-
phil in the parenchyma of lymph nodes 
under basal conditions10). The dynamics 
of their journey is mainly unknown and 
there is still uncertainty whether the 
recruitment is via the bronchial or pulmo-
nary circulation in humans, or both. 
Previous studies, in vivo, suggested that 
the lung contained a physiological, margi-
nated pool of neutrophils, due to the time 
required to attain the conformational 
changes needed to allow neutrophils to 
pass through the narrow pulmonary capil-
laries, as described in a number of animal 
models and reviews.11 However, careful 
work using autologous radiolabelled 
neutrophils and single-photon emission 
CT over the thorax/upper abdomen at 45 
min, 2 hours, 4 hours and 6 hours to deter-
mine blood neutrophil clearance from the 
lung have shed much light on this theory 
in humans. Initially, Summers et al demon-
strated that unprimed neutrophils passed 
through the lungs with a transit time only 
a fraction slower than erythrocytes, and 
with minimal first-pass retention, but that 
priming (and inflammatory lung condi-
tions, such as Acute Respiratory Distress 
Syndrome (ARDS)) led to neutrophil 
retention in the lungs (with the priming 
agent dictating if retention was likely to 
be a short-term or longer-term event).12 
These studies suggested that some of the 
previous data might reflect neutrophil 
activation in the hands of the researcher. 
Then, in vitro, using an optical stretcher 
and a microcirculation mimetic, the group 
described how the continued mechanical 
deformation of primed neutrophils caused 
active depolarisation (and depriming),13 
suggesting that the tortuous pulmonary 
capillary bed might not be a site of cell 
capture, but instead a vital mechanism to 
prevent widespread tissue damage caused 
by an army of activated neutrophils in the 
circulation.
The current paper14 builds on these 
findings to study the effect of an acute 
inflammatory challenge in health and in 
patients with COPD. In the stable state, 
neutrophil accumulation is increased in 
COPD patients compared with healthy 
individuals with little overlap. Further-
more, the process can be modulated (here 
in healthy controls) using an inhaled lipo-
polysaccharide (LPS) challenge, simulating 
an acute infection.
The dynamic retention of neutrophils 
in the lungs is clearly a feature of COPD 
and was reproducible in the stable clinical 
state, enabling this methodology to be used 
to assess factors that can modulate neutro-
phil retention to the lung, beneficially or 
adversely. This study also highlighted the 
heterogeneity of signal in COPD lungs, 
which is concordant with the heteroge-
nous burden of pathology throughout the 
lung, the increased retention of neutro-
phils in patients with chronic bronchitis (a 
subgroup that notably experience a higher 
burden of neutrophilic inflammation) and 
the reduced signal in areas of large bullae 
(potentially reflecting the loss of the capil-
lary bed in these areas15). These studies 
answered the first question we posed 
in COPD, neutrophils are clearly being 
retained in the lungs for longer than in 
health, and in great numbers.
Currently, these results provide a global 
lung observation and cannot compart-
mentalise findings to areas of interest or 
tissue damage (eg, focusing on the upper 
zones in areas of emphysema or to the 
bronchial tree in patients with a chronic 
bronchitis/colonisation phenotype)—the 
current methodology cannot answer ques-
tion 2, the ‘where’. The authors describe a 
weak signal in bullous areas (as expected 
as there is less tissue); however, combining 
techniques might provide insight. For 
example, correcting for lung density may 
indicate a high signal to mass ratio in these 
specific emphysematous areas as seen with 
positron emission tomography (PET) CT 
scanning,16 providing further evidence of 
the role of the neutrophil in this destruc-
tive process. The issue relates to whether 
the rate of accumulation and the zonal site 
of accumulation is critical in disease devel-
opment and pathology. Clearly, the bron-
chitis phenotype shown here is important 
in the signal and bronchitis is associated 
with a more rapid decline in FEV1,
17 as is 
the emphysema phenotype.18
This methodology cannot, as yet, 
answer the third question, why neutrophils 
are retained. The LPS challenge model 
suggests it is a response to local inflamma-
tion induced in health, where the normal 
lung architecture is preserved. In COPD, 
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the chronic inflammatory environment is 
coupled with tissue damage and remod-
elling. The damaged capillary networks 
may be less able to orchestrate neutrophil 
depolarisation, and thus slow depriming, 
promoting cells getting ‘stuck’ in the 
pulmonary vasculature. However, there is 
also evidence of neutrophil dysfunction in 
COPD, displaying increased polarisation 
associated with phosphoinositol kinase 
activity,19 potentially highlighting neutro-
phil-dependent mechanisms, which retain 
the cells in situ.
And so to the final question posed. Can 
this complex methodology tell us more 
than cross-sectional data in phase 2 studies, 
where airway secretion neutrophil count 
can be shown to respond to anti-inflam-
matory therapy (eg, in the studies of roflu-
milast20)? The answer is probably ‘Yes’. 
Cell counts in airway secretions are based 
on the sampling moment and influenced 
by dilutional factors in collection and rate 
of airways clearance, such as expecto-
ration and efferocytosis. The lungs need 
neutrophils at certain times and physio-
logical recruitment is essential for health, 
but standard sputum sampling techniques 
are a blunt tool to assess subtle shifts in 
the dynamics of neutrophil recruitment 
and clearance. The strength of the tech-
nique described in the current study lies 
in its ability to monitor uptake dynam-
ically. The methodology would permit 
tracking of the rate of neutrophil reten-
tion against progression, studying patients 
with a fast decline in FEV1 to potentially 
develop treatments to normalise neutro-
phil retention rates. Furthermore, this 
technique could confirm that any therapy 
that reduced baseline recruitment to the 
lungs would still permit increased recruit-
ment when needed, utilising appropriate 
challenges. This may indeed prove a new 
dimension to understanding the dynamics 
of neutrophil recruitment and its modula-
tion in both health and disease.
Its weakness is the intricacy of the 
measure, using time-consuming meth-
odology with specialised equipment that 
may limit availability and compliance, 
especially in more severe disease and 
during episodes of destabilisation. The 
studies currently determine neutrophil 
clearance using an assessment over all the 
time points of data capture, suggesting the 
study of one patient would take at least 
8 hours. Such studies may need to be 
focused on patients with ‘earlier/milder’ 
disease who may be better able to manage 
the time-consuming protocol required. 
However, given the faster rate of FEV1 
decline in this patient group, this may well 
be where we should be concentrating our 
best efforts in disease prevention.
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